Beam Therapeutics Inc.
BEAM
$23.91
$0.944.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 60.27M | 63.58M | 63.52M | 349.64M | 352.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.27M | 63.58M | 63.52M | 349.64M | 352.57M |
| Cost of Revenue | 226.27M | 230.24M | 232.15M | 270.78M | 276.58M |
| Gross Profit | -166.00M | -166.66M | -168.63M | 78.86M | 75.99M |
| SG&A Expenses | 109.97M | 112.74M | 111.53M | 126.12M | 125.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 506.25M | 494.30M | 479.09M | 532.32M | 537.00M |
| Operating Income | -445.98M | -430.72M | -415.57M | -182.67M | -184.44M |
| Income Before Tax | -398.58M | -387.30M | -376.70M | -142.19M | -141.61M |
| Income Tax Expenses | 0.00 | 39.00K | 39.00K | 1.41M | 1.41M |
| Earnings from Continuing Operations | -398.58 | -387.34 | -376.74 | -143.59 | -143.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -398.58M | -387.34M | -376.74M | -143.59M | -143.01M |
| EBIT | -445.98M | -430.72M | -415.57M | -182.67M | -184.44M |
| EBITDA | -423.99M | -408.70M | -393.64M | -160.83M | -162.88M |
| EPS Basic | -4.51 | -4.61 | -4.58 | -1.72 | -1.76 |
| Normalized Basic EPS | -2.81 | -2.80 | -2.77 | -0.99 | -0.99 |
| EPS Diluted | -4.51 | -4.62 | -4.58 | -1.76 | -1.81 |
| Normalized Diluted EPS | -2.81 | -2.80 | -2.77 | -1.01 | -1.01 |
| Average Basic Shares Outstanding | 355.20M | 335.52M | 329.25M | 327.28M | 323.89M |
| Average Diluted Shares Outstanding | 355.20M | 335.52M | 329.25M | 329.12M | 325.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |